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Inflammation involving the innate and adaptive immune systems is a normal response to infection.
However, when allowed to continue unchecked, inflammation may result in autoimmune or autoin-
flammatory disorders, neurodegenerative disease, or cancer. A variety of safe and effective anti-
inflammatory agents are available, including aspirin and other nonsteroidal anti-inflammatories,
with many more drugs under development. In particular, the new era of anti-inflammatory agents
includes ‘‘biologicals’’ such as anticytokine therapies and small molecules that block the activity
of kinases. Other anti-inflammatories currently in use or under development include statins, histone
deacetylase inhibitors, PPAR agonists, and small RNAs. This Review discusses the current status
of anti-inflammatory drug research and the development of new anti-inflammatory therapeutics.Introduction
Reducing pain, inflammation, and fever with salicylate-contain-
ing plant extracts can be traced throughout written human
history. One hundred and fifty years ago, Felix Hoffman acety-
lated salicylic acid and created aspirin. Aspirin inhibits the
cyclooxygenase (COX) enzymes COX-1 and COX-2, which
synthesize inflammatory mediators called prostaglandins and
thromboxanes. The ability to block production of prostaglandins
and thromboxanes accounts for aspirin being the world’s most
used therapeutic agent. Second to aspirin are nonsteroidal
anti-inflammatory drugs (NSAIDS), which target COX-2 and
hence the synthesis of prostaglandins, particularly PGE2. Syn-
thetic forms of natural cortisol (termed glucocorticoids) are
also widely used to treat many inflammatory diseases, and
despite their side effects, glucocorticoids remain a mainstay
for reducing inflammation. Yet, it is still the challenge of the phar-
maceutical chemist to develop more effective and less toxic
agents to treat the signs and symptoms of acute inflammation
as well as the long-term consequences of chronic inflammatory
diseases.
Inflammation is a dynamic process with proinflammatory cyto-
kines such as tumor necrosis factor (TNF)-a, interleukin (IL)-1b,
and vascular endothelial growth factor (VEGF) playing central
roles. A number of ‘‘biologicals’’ have been developed to treat
inflammation (Table 1), including agents that reduce the activity
of specific cytokines or their receptors (anticytokine therapies),
block lymphocyte trafficking into tissues, prevent the binding
of monocyte-lymphocyte costimulatory molecules, or deplete
B lymphocytes (Figure 1). Current anticytokine therapies have
found a place in the treatment of autoimmune diseases, such
as rheumatoid arthritis, inflammatory bowel disease, psoriasis,
multiple sclerosis, and others. Without question, neutralization
of specific proinflammatory cytokines has ‘‘canonized’’ their
causative role in inflammation and has changed the lives of
millions of patients with these diseases. One drawback of anticy-tokine therapies is decreased host immune defense against
infection and possibly cancer. Nevertheless, the benefits of anti-
cytokine therapies outweigh the risks, and the risks can be
reduced. Compared to the consequences of long-term gluco-
corticoid treatment to stem inflammation, anticytokine thera-
pies are a major improvement. Indeed, organ toxicities are
rarely, if ever, observed with anticytokine therapies as they oper-
ate almost exclusively in extracellular rather than intracellular
compartments.
Kinases that act downstream of cytokine receptors have
become new targets to tame inflammation, and orally active
small-molecule inhibitors of intracellular signaling kinases will
likely be the new frontier of anti-inflammatory drug development.
However, because many intracellular signaling molecules are
involved in normal cellular functions, the effective concentration
that does not elicit organ toxicity will need to be carefully deter-
mined. Statins, a safe class of drugs used for lowering serum
cholesterol, also have anti-inflammatory properties. Orally active
inhibitors of histone deacetylases, which are also safe and used
clinically, are effective drugs with anti-inflammatory properties
that also block cell proliferation. Naturally occurring resolvins
are also being developed as anti-inflammatory agents. This
Review discusses current anti-inflammatory drugs as well as
the development of new orally active, safe, and effective drugs
for treating acute or chronic inflammation.
Inhibiting Prostaglandins: Targeting COX-2
The inflammatory molecule PGE2 lowers pain thresholds, and
the primary goal of oral inhibitors of PGE2 is to reduce pain.
There are two pathways for synthesizing the inflammatory mole-
cule PGE2: the constitutive COX- 1 pathway and the inducible
COX-2 pathway. Whereas COX-1 accounts for low levels of
PGE2 and regulates homeostatic mechanisms in health, COX-2
induces at least two orders of magnitude more PGE2 compared
to COX-1 and is primarily associated with inflammatory disease.Cell 140, 935–950, March 19, 2010 ª2010 Elsevier Inc. 935
Table 1. Biologicals in the Treatment of Chronic Autoimmune and Inflammatory Diseases
Drugs Function Diseases Treated
Anti-CD3 (eplizumab); anti-IL-2 receptor MoAb (daclizumab) Targeting T cells Transplant rejection;
Type 1 diabetes
Anti-CD20 (rituximab, crelizumab, ofatumumab); anti-CD22 (epratuzumab);
anti-Blys MoAb IgG1 (belimumab)
Targeting B cells Type 1 diabetes; rheumatoid
arthritis; multiple sclerosis
Anti-TNF-a MoA (infliximab, adulimumab, golimumab); anti-TNF-a pegylated
Fab’ (certolizumab); soluble TNF p75 receptor Fc fusion (etanercept)
Reducing TNF-a
activities
Rheumatoid arthritis;
Crohn’s disease; psoriasis
Anti-IL-6 MoAb (MEDI5117); Anti-IL-6 receptor (toculizumab) Reducing IL-6
activities
Rheumatoid arthritis;
juvenile arthritis
Anti-IL-12/23 (ustekinumab); Anti-IL-17 MoAb (AIN457/LY24398) Neutralization of IL-12,
IL-23, and IL-17
Rheumatoid arthritis;
Crohn’s Disease; psoriasis
IL-1 receptor antagonist (anakinra); soluble IL-1 receptor (rilonacept); anti-IL-1b
(IgG1) (canakinumab); anti-IL-1b (IgG2) (Xoma 052); anti-IL-1R MoAb IgG1 (AMG 108)
Reducing IL-1b
activities
Autoinflammatory
diseases (see Table S1)
Anti-a4 integrins MoAb (natalizumab); anti-LFA-1 MoAb (efalizumab) Blocking cell adhesion
and migration
Multiple sclerosis; Crohn’s
Disease; psoriasis
CTLA-4 Ig fusion protein (abatacept) Blocking T cell
coreceptors
Type 1 diabetes;
rheumatoid arthritisSynthesis of COX-2 is absent or low in healthy individuals but is
upregulated by proinflammatory cytokines such as IL-1 and
TNF-a in response to infection or in inflammatory disease.
Specific inhibitors of COX-2 have provided a major advance in
the treatment of pain, particularly in patients with osteoarthritis
or rheumatoid arthritis. For the most part, COX-2 inhibitors
have significantly reduced gastrointestinal side effects com-
pared to COX-1 inhibitors. However, the chronic use of some
COX-2-specific inhibitors has been associated with an increase
in cardiovascular as well as cerebrovascular events particularly
in patients with an elevated risk of thrombosis. This increased
risk may be due to the COX-2-mediated reduction in synthe-
sis of prostacyclin, which is a natural inhibitor of platelet activa-
tion. In addition to their widespread benefit in arthritis, COX-2-
specific inhibitors are used to reduce the development of colon
cancer in high-risk patients as adenocarcinoma cells in the colon
overexpress COX-2. There is still a need to develop safer, more
effective COX-2 inhibitors.
Resolvins
There are several steps in the initial inflammatory cascade
triggered by cytokines, including recruitment of myeloid cells
(monocytes and neutrophils) into affected tissues (Figure 1).
Inflammatory products of arachidonic acid oxidation (omega-6)
including inflammatory prostaglandins (PGE2) and lipoxins
(LTB4) are released from infiltrating myeloid cells. In contrast,
products of eicosapentanoic acid (omega-3) oxidation, PGE3,
and LTB5, have anti-inflammatory activities. Products of
omega-3 fatty acid oxidation include resolvins of the E series
(RvE1 and RvE2) (Serhan and Chiang, 2008), which are found
naturally in nearly all inflammatory sites in mammals. The D
series of resolvins are derived from docosahexaenoic acid.
Specific receptors for resolvins have been identified and when
activated are functional in reducing inflammation (Krishnamoor-
thy et al., 2010). In general, resolvins are part of the anti-inflam-
matory portfolio that coexists with inflammation. Synthetic forms
of RvE1 are currently in clinical trials for treating ocular diseases
and other local inflammatory conditions. In animal models of936 Cell 140, 935–950, March 19, 2010 ª2010 Elsevier Inc.sterile inflammation, RvE1 suppresses the number of infiltrating
neutrophils and macrophages as well as decreasing expression
of the genes encoding TNF-a, IL-1b, and VEGF (Jin et al., 2009).
The anti-inflammatory properties of omega-3 fatty acids include
suppression of IL-1b and TNF-a production (Endres et al., 1989),
and themechanism of action of omega-3 fatty acids may include
boosting production of resolvins of the D and E series.
Glucocorticoids: Suppressing Cytokine-Driven
Inflammation
Glucocorticoids are used widely on a chronic basis to treat most
autoimmune diseases. Short-term glucocorticoid treatment is
used in gout, and intra-articular injections of glucocorticoids
are commonly used to treat painful osteoarthritic joints and
tendonitis. Although there are several mechanisms by which
glucocorticoids reduce inflammation, a major one may be to
reduce expression of cytokine-induced genes. Glucocorticoids
enter all cells and bind to the cytoplasmic steroid receptor, and
then this complex translocates to the nucleus where it is recog-
nized by specific DNA sequences. The major effect of binding to
DNA is the suppression of transcription by opposing the activa-
tion of the transcription factors AP-1 and NF-kB. AP-1 and
NF-kB induce expression of genes encoding nearly all proinflam-
matory cytokines. Glucocorticoids also suppress expression of
inflammatory genes encoding T cell growth factors such as
IL-2, IL-4, IL-15, and IL-17 aswell as interferon-g (IFN-g). In addi-
tion, glucocorticoids reduce expression of genes encoding
COX-2, inducible nitric oxide synthase, and intracellular adhe-
sion molecule-1 (ICAM-1), which are normally induced by the
cytokines IL-1b and TNF-a. Glucocorticoids increase expression
of genes encoding anti-inflammatory molecules, such as the
cytokine IL-10 and the IL-1 type 2 decoy receptor.
Biologicals as Anti-inflammatory Agents
Anticytokine Therapies
Although cytokines are studied in nearly every biological disci-
pline, cytokine-mediated effects often dominate the fields of
inflammation, immunology, atherosclerosis, and degenerative
Figure 1. Inflammation and Points of Inhibi-
tion by Anti-inflammatory Agents
Shown is the inflammatory pathway associated
with ischemia-induced tissue damage and the
anti-inflammatory drugs that can be used to block
inflammation at various points in the pathway.
During ischemia, mesenchymal-derived cells
undergo hypoxic damage, lose membrane integ-
rity, and release their cytoplasmic contents.
This is followed by the release of biologically active
proinflammatory cytokines such as IL-1 and
VEGF. These cytokines bind to and activate their
cognate receptors on nearby macrophages. The
activation of the cytokine receptors triggers
tissue-residentmacrophages to express an exten-
sive portfolio of proinflammatory genes. Some
gene products such as the IL-1b and IL-18
precursor proteins require processing by cas-
pase-1 and secretion as active cytokines. There
is also chemokine production by activated tis-
sue macrophages. A concentration gradient
of secreted cytokines and chemokines forms
between the macrophage and the endothelium of
the microvasculature. Activation of cytokine and
chemokine receptors on the endothelium takes
place resulting in the opening of endothelial
junctions. This leads to a capillary leak and the
passage of plasma proteins into the ischemic
area. During the ischemic event, there is activation
of complement with induction of cytokines and
chemokines, as well as a direct effect of C5a on
chemoattraction. As part of the cytokine activation
of the endothelium, there is expression of the
adhesion molecule VCAM-1, which facilitates the
rolling of innate immune cells such as monocytes
and neutrophils (myeloid cells) and their adherence to the endothelium. These inflammatory cells then leave the circulation and enter the tissue space by diape-
desis. With increasing numbers of infiltrating myeloid cells, the healthy tissue surrounding the ischemic area (called the penumbra) is subjected to damage
from the cellular infiltrate due to the release of cytokines and chemokines into the penumbral tissue. Release of damaging proteases from neutrophils contributes
to the loss of tissue in the penumbra. Adherence of platelets to the endothelium causes further endothelial activation by increasing expression of receptors for
platelets. During the development of an inflammatory infiltrate in the ischemic tissue, a cascade of clotting factors is initiated by cytokine-induced endothelial
tissue factor. In addition, the cytokine-activated endothelium releases inhibitors of fibrinolysis. With increased coagulation in themicrovasculature and decreased
fibrinolysis, tissue perfusion slows and hypoxia and tissue damage worsen.processes of aging. In addition, cytokine-driven chronic inflam-
mation has been implicated in cancer formation as well as
metastasis (see Review by S.I. Grivennikov et al. on page 883
of this issue). Cytokines are secreted by one cell and act on
another cell in order to bring about a change in the function of
the target cell. In a way, one can consider cytokines as the ‘‘hor-
mones’’ of inflammatory responses, but whereas a hormone is
the primary product of a specialized cell, cytokines can be
produced by many different cell types including those of the
immune system and epithelia. On a molar basis, cytokines are
far more potent than hormones. For example, the concentration
of IL-1 that induces COX-2 is 10 pM and the concentration of
IL-12 that induces IFN-g is 20 pM. In terms of anticytokine ther-
apies, the amount of a neutralizing antibody or soluble receptor
that blocks the activity of a cytokine can be relatively low
compared to the amount of antibody needed to kill a microbe.
Blocking the activity of the proinflammatory cytokines IL-1,
TNF, IL-6, IL-12, IL-17, IL-18, or IL-23 reduces inflammation
and suppresses specific pathways that activate T cells. Blocking
IL-32 and IL-33 may also be useful for treating inflammation aswell as allergy. Chemokines are also cytokines, and small-mole-
cule chemokine receptor antagonists have been used to treat
Crohn’s disease, an autoimmune inflammatory bowel disease
(Proudfoot et al., 2010). Chemokines drive the migration of
immune cells but they also affect angiogenesis and the activity
of myeloid cells.
Anticytokine Therapies and Host Defense
The conundrum in considering anticytokine therapies for treating
chronic diseases is that cytokines evolvedmanymillions of years
ago and provided a survival benefit for the host through what is
now termed the ‘‘innate immune response.’’ The innate immune
response is less specific than the adaptive immune response
and is the first line of defense against infection or injury. It is char-
acterized by an inflammatory response involving infiltration of
neutrophils in response to cytokines resulting in phagocytosis
and intracellular killing of the pathogens and the control of infec-
tion. In most cases, even without antibiotics, the inflammation
subsides once the infection is eliminated, and there is little or
no damage to the host. In fact, cytokines produced during
inflammation also assist in the repair process after injury.Cell 140, 935–950, March 19, 2010 ª2010 Elsevier Inc. 937
However, the same cytokines that orchestrate the infiltration of
neutrophils acutely in order to fight infection are responsible
for tissue remodeling and organ damage when produced chron-
ically. Chronic inflammation destroys the joints, the ability of lung
tissue to exchange gases, the patency of blood vessels, the
intestinal barrier, and the myelin sheath that insulates nerve
fibers in the brain and spinal cord. Hence, even though their
primary function is to protect the host when challenged and to
repair tissue when injured, these cytokines are mediators of
disease and thus are targets for anticytokine therapy. Another
paradox is provided by IFN-g, which is essential for defense
against intracellular microorganisms such as Mycobacterium
tuberculosis, which causes tuberculosis. IFN-g is also a major
cytokine in the pathogenesis of several autoimmune diseases
including multiple sclerosis, psoriasis, and lupus.
Blocking cytokines may reduce inflammation but also renders
the host susceptible to infection and maybe even cancer. Anti-
TNF-a treatment increases opportunistic infections (reviewed
in Dinarello, 2005). On the other hand, anticytokine therapy has
little or no organ toxicity or gastrointestinal disturbances and
so is well tolerated.
Biologicals for Treating Autoimmune Diseases
Autoimmune versus Autoinflammatory Diseases
Some chronic inflammatory diseases are autoimmune, whereas
others are ‘‘autoinflammatory.’’ In autoimmune diseases, the
T cell dominates as the primary dysfunctional cell or initiator of
the disease process. A cluster of cytokines such as TNF-a,
IFN-g, IL-2, IL-12, IL-23, and IL-17 participate in maintaining
autoreactive T cells. Rheumatoid arthritis, inflammatory bowel
disease, type 1 diabetes, psoriasis, lupus, and multiple sclerosis
are examples of autoimmune diseases in which the inflamma-
tion is secondary to a disease process that is driven by autoreac-
tive T cells (See Essay by L.A. Zenewicz et al., in this issue).
In contrast, autoinflammatory diseases are not mediated by
the adaptive immune system and do not involve T cells but
rather are caused by dysfunctional macrophages (see Essay
by D.L. Kastner et al. in this issue). Themechanism of autoinflam-
matory disease appears to be due to increased secretion of
IL-1b, and treatment is uniquely based on reducing the activity
of IL-1b.
Most autoimmune diseases can be treated with any one of
a number of ‘‘biologicals’’ (Table 1). The best example is rheuma-
toid arthritis where neutralizing TNF-a, blocking IL-6 receptors,
depleting B lymphocytes, or preventing T cell costimulation are
all effective therapeutic approaches. Even blocking IL-1 recep-
tors or neutralizing IL-1b is effective for treating rheumatoid
arthritis, but this effect is due to protection of bone and cartilage
rather than reduction of T cell activation. Thus, preventing the
activity of only one cytokine or reducing the effect of one
pathway can be effective in treating autoimmune diseases.
Other examples include psoriasis and Crohn’s disease, which
can be effectively treated by blocking IL-12, IL-23, or TNF-a or
by using a humanizedmonoclonal antibody to block a4 integrins.
For example, a monoclonal antibody directed against a4 integ-
rins (natalizumab) prevents the migration of immune cells into
tissues. One goal in treating autoimmune disease is to reduce
the infiltration of autoreactive T cells into the affected tissue.938 Cell 140, 935–950, March 19, 2010 ª2010 Elsevier Inc.Another is the depletion of B cells using anti-CD20 monoclonal
antibodies such as rituximab, ocrelizumab, or ofatumumab.
Biologicals offer several options for treating autoimmune
diseases. Although the field of biologicals began with the use
of anti-TNF-a monoclonal antibodies to treat Crohn’s Disease,
it has expanded considerably. Antibodies to IL-12, IL-17, IL-23,
IL-1b, and the IL-6 receptor have been approved, and antibodies
to IL-23 and IL-17 are in clinical trials. Each ‘‘biological’’ can be
effective in the treatment of more than one autoimmune disease,
suggesting that there is considerable overlap in cytokine func-
tions in inflammation. The success of a ‘‘biological’’ is best
observed in patients with poorly controlled disease who are
receiving the standard of therapy for that disease, for example
rheumatoid arthritis. Adding a biological to standard therapy
often decreases disease severity. The physician has an increas-
ing list of biologicals from which to choose: anti-TNF-a anti-
bodies or soluble TNF receptors to neutralize TNF-a, anti-IL-6
receptor antibodies to block IL-6, CTLA-4-Ig to block the binding
of costimulatory molecules, rituximab (an anti-CD20 monoclonal
antibody) to deplete B cells, neutralizing antibodies to block
IL-12 and IL-23 activity, or natalizumab to reduce lymphocyte
trafficking. Although the degree of benefit will differ depending
on the patient, most experience improved control of their
disease.
Why Just One?
Despite the multiple cellular and cytokine-mediated mecha-
nisms for sustaining autoimmune diseases, blocking just one
cytokine can be sufficient to bring the disease under control.
Why is this? There is evidence that cytokines exist in ‘‘cascades’’
and that interrupting one cytokine interrupts the cascade.
For example, blocking TNF-a reduces the activity of IL-6 and
IL-1b (Dinarello et al., 1986; Fong et al., 1989), blocking IL-1b
reduces IL-6 (Fitzgerald et al., 2005; Goldbach-Mansky et al.,
2006; Hoffman et al., 2004; Pascual et al., 2005), and blocking
IL-12 and IL-23 reduces IFN-g. B lymphocytes make TNF-a
and IL-1b, and this may account for the beneficial effects of
depleting B cells with monoclonal antibodies. IL-12 and IL-23
sustain production of IL-17, which may explain the success of
using IL-12 and IL-23 inhibitors to treat autoimmune diseases.
There is also ample evidence that cytokines act in a synergistic
rather than additive fashion. For example, synergistic cytokine
pairs include IL-1 and TNF-a, TNF-a and IFN-g, and IL-1b and
IL-6 (reviewed in Dinarello, 1996, 2009a). Thus, blocking one
cytokine interrupts this synergy and reduces disease severity.
Part of the success of TNF-a inhibitors for treating rheumatoid
arthritis, Crohn’s disease, and psoriasis is the loss of TNF-a-
bearing T cells. TNF-a is located on the T cell surface and anti-
TNF-a monoclonal antibodies of the IgG1 class crosslink mem-
brane TNF-a and induce death of T cells (reviewed in Dinarello,
2005).
Autoimmune Disease and B Cell Depletion
Rituximab and other monoclonal antibodies that target and
deplete CD20-positive B cells have an unexpected benefit in
treating rheumatoid arthritis, psoriasis, Crohn’s disease, multiple
sclerosis, and type 1 diabetes (Table 1). Although depletion of
B cells reduces immunoglobulin levels, this is unlikely to explain
the efficacy of B cell depletion for treating these autoimmune
diseases. B cells contribute to antigen presentation and thus
help in T cell activation. Also, increasing evidence links the path-
ogenesis of most autoimmune diseases with T cells producing
IL-17. IL-17 is a proinflammatory cytokine that induces chemo-
kine production and promotes infiltration of neutrophils and
macrophages. There was a marked reduction in IL-17 produced
by synovial cells from the joints of rheumatoid arthritis patients
treated with rituximab (van de Veerdonk et al., 2009b). In periph-
eral bloodmononuclear cells, the presence of rituximab reduced
the levels of IL-17 as well as the number of T cells producing the
cytokine.
Side Effects of Biologicals
Themajor side effect of biologicals is a reduction in host defense
against infections. When detected early, these infections can be
effectively treated with antibiotics. However, three biologicals
used to treat autoimmune diseases have resulted in cases of
progressive multifocal leukoencephalopathy (PML). PML is
a rapidly demyelinating and potentially fatal disease that is
caused by a virus and is often observed in patients treated
with immunosuppressive drugs or in patients with AIDS. PML
has been associated with patients with multiple sclerosis or
Crohn’s disease treated with the monoclonal antibody natalizu-
mab (Major, 2009). PML also develops in patients treated with
the B cell-depleting antibody rituximab and in psoriasis patients
treated with the monoclonal antibody efalizumab. Natalizumab
and efalizumab prevent the migration of T cells into tissues,
whereas rituximab lyses CD20-bearing B cells and does not
affect T cell migration. It is not clear why natalizumab, rituximab,
or efalizumab cause PML.
Biologicals for Treating Autoinflammatory Diseases
Autoinflammatory diseases are chronic inflammatory conditions
characterized by macrophage dysfunction and local as well as
systemic inflammation (see Essay by D.L. Kastner et al. in this
issue; Table S1 available online). Autoinflammatory diseases
are noninfectious but can be exacerbated by infection. Recur-
rent fevers are common, with painful joints and muscles and
elevated blood neutrophil counts. By inhibiting only IL-1b, these
diseases rapidly are brought under control; neutralization of
TNF-a has little or no effect. Some of these debilitating diseases
are due to gain-of-function mutations that affect the activation of
caspase-1, which leads to increased processing of the inactive
IL-1b precursor and release of active IL-1b (reviewed in Masters
et al., 2009). Caspase-1 activation is initiated by the ‘‘inflamma-
some,’’ a multiprotein intracellular complex (see Review by
K. Schroder and J. Tschopp on page 821 of this issue). The
first mutation affecting the processing of IL-1b was discovered
in the nucleotide-binding domain and leucine-rich repeat con-
taining protein 3 (NLRP3), a component of the inflammasome
(Hoffman et al., 2001). Mutations associated with the classic
autoinflammatory disease familial Mediterranean fever also
increase the secretion of IL-1b (Masters et al., 2009). Another
classic autoinflammatory disease is hyper-IgD (Drenth et al.,
1999). Mutations in the gene encoding mevalonate kinase cause
hyper-IgD and also periodic fever syndrome (International
Hyper-IgD Study Group). In each of these diseases, IL-1b can
stimulate its own production, which plays a pivotal role in
autoinflammatory disease pathogenesis (Dinarello et al., 1987;
Gattorno et al., 2007).Is Type 2 Diabetes an Autoinflammatory Disease?
Type 1 diabetes is a classic autoimmune disease in which autor-
eactive T cells attack the insulin-producing b cells of the
pancreas. On the other hand, in type 2 diabetes, there is no
T cell involvement but rather a chronic state of inflammation
in which IL-1b is produced and kills the b cells. Thus, type 2
diabetes falls into the autoinflammatory class of diseases, and
the beneficial effects of IL-1b blockade in patients with type 2
diabetes supports that concept. IL-1b is also cytotoxic for
b islet cells in autoimmune type 1 diabetes (Mandrup-Poulsen
et al., 1986), but in type 2 diabetes high levels of glucose can
stimulate IL-1b production by the b islet cell itself (Maedler
et al., 2002). IL-1b is also produced by fat cells, an additional
source of IL-1b in type 2 diabetes. In general, the loss of b cell
mass in the pancreas progresses over several years during
which time patients are in a ‘‘pre-diabetic’’ state. It is therefore
possible to ‘‘salvage’’ b islet cells by reducing IL-1b-mediated
inflammation.
Proof of a specific role for IL-1b in the pathogenesis of type 2
diabetes was demonstrated in patients in a 13week randomized,
placebo-controlled study using the IL-1 receptor antagonist
(IL-1Ra), also called anakinra, to block IL-1b. There was a statis-
tically and clinically significant improvement in insulin production
and glycemic control (Larsen et al., 2007a). The clinical response
to anakinra was linked to variants in the gene encoding IL-1Ra
that result in low circulating levels of IL-1Ra (Larsen et al.,
2009), raising the possibility that insufficient IL-1Ra contributes
to inflammation in type 2 diabetes. In the 39 weeks after anakinra
treatment, patients who responded to anakinra used 66% less
insulin to obtain the same level of glycemic control. This obser-
vation suggests that blocking IL-1b even for a short period
restores the function of pancreatic b cells or possibly allows for
some regeneration of b cells. Several trials blocking TNF-a in
type 2 diabetes have succeeded in reducing C-reactive protein
but did not improve glycemic control. The anakinra trial observa-
tions have been confirmed using a specific neutralizing mono-
clonal antibody to IL-1b (Donath et al., 2009). These studies
provide clinical evidence that type 2 diabetes is a chronic auto-
inflammatory disease in which IL-1b-mediated inflammation
progressively destroys the insulin-producing pancreatic b cells.
In diabetic mice, administration of a caspase-1 inhibitor
reduces insulin resistance; in mice deficient in caspase-1, there
is improved sensitivity to insulin (Stienstra et al., 2009). In addi-
tion, the thioredoxin-interacting protein (TXNIP) binds to NLRP3,
which activates caspase-1 and the subsequent processing and
secretion of active IL-1b (Zhou et al., 2010). TXNIP-deficient mice
exhibit improved glucose tolerance and reduced insulin resis-
tance (Zhou et al., 2010). There are several studies linking TXNIP
expression to type 2 diabetes and glucose regulation. Thus, it
appears that in insulin-secreting pancreatic b cells, glucose-
stimulated IL-1b activity is caspase-1 dependent; production
of IL-1b by adipocytes is also caspase-1 dependent (Stienstra
et al., 2009).
IL-1 Blockade in Stroke and Heart Disease
IL-1 receptor blockade in stroke patients results in a decrease in
circulating neutrophils and IL-6 levels, which is often associated
with a reduction in IL-1b activity. Moreover, the severity of neu-
rological impairment appears to decrease in stroke patientsCell 140, 935–950, March 19, 2010 ª2010 Elsevier Inc. 939
Figure 2. Production and Release of IL-1b
(Top left) Primary blood monocytes, tissue macro-
phages, or dendritic cells are activated by the
cytokine IL-1b (blue oval) resulting in the formation
of the IL-1 receptor complex (composed of IL-1RI
and IL-1RAcP). The intracellular TIR domains of
the IL-1 receptor complex recruit MyD88 and
other signaling components leading to transloca-
tion of the transcription factor NF-kB into the
nucleus. This results in transcription of the gene
encoding the precursor of IL-1b and its translation
into protein (blue dumb-bell) (Bocker et al., 2001).
ATP released from activated monocytes (or from
dying cells) accumulates outside the cell. As the
extracellular levels of ATP increase, the P2X7
receptor is activated, triggering the efflux of potas-
sium ions from the cell. Low intracellular potas-
sium ion levels enable the components of the cas-
pase-1 inflammasome to assemble. Assembly
results in the conversion of procaspase-1 to active
caspase-1. There is evidence that the compo-
nents of the inflammasome localize to secretory
lysosomes together with the IL-1b precursor
protein and lysosomal enzymes (Andrei et al.,
2004). In the secretory lysosome, active cas-
pase-1 cleaves the IL-1b precursor, generating active mature IL-1b. Mature IL-1b is released along with the IL-1b precursor and the contents of the secretory
lysosomes (Andrei et al., 2004). There is evidence that secretion of active IL-1b requires an increase in intracellular calcium ion levels (Kahlenberg and Dubyak,
2004). Processing of the IL-1b precursor can also take place in the cytosol independently of caspase-1 and the inflammasome (Brough and Rothwell, 2007).
Studies have also shown that Rab39a, a member of the GTPase family, contributes to the secretion of mature IL-1b by helping IL-1b traffic from the cytosol
into the vesicular compartment (Becker et al., 2009) from where it is secreted by exocytosis (Qu et al., 2007) (not shown). Mature IL-1b can also exit the cell
through a loss in membrane integrity (Laliberte et al., 1999) or exocytosis via small vesicles (MacKenzie et al., 2001).treated with IL-1 receptor blockade compared to placebo-
treated controls (Emsley et al., 2005). Does IL-1 contribute to
heart failure after myocardial infarction? Animal studies show
that reducing IL-1 activity prevents post-infarction myocardial
remodeling (Abbate et al., 2008). In a placebo-controlled trial of
anakinra in patients with myocardial infarction, daily anakinra
treatment was added to standard therapy the day after angio-
plasty and continued for 14 days. Three months later, there
was a statistically significant difference in the left ventricular
end-systolic volume index (a surrogate marker of damage
severity in myocardial infarction) in patients treated with anakinra
compared to patients given a placebo (Abbate et al., 2010). The
mechanism for the beneficial effect of the 14 day course of
therapy is likely to be due to a reduction in themyocardial remod-
eling that takes place after loss of viable heart muscle, and that
results in heart failure. The heart seems to be exquisitely sensi-
tive to IL-1 blockade as the amount of anakinra used to treat
the myocardial infarction patients was the same as that used in
rheumatoid arthritis, that is, 100 mg subcutaneously each day.
This dose results in a brief (4 hr) rise in blood levels not more
than 1.0 mg/ml.
Agents for Blocking IL-1 Activity
Specific monoclonal antibodies, such as canakinumab and
Xoma 052, are the best agents for blocking IL-1b activity. Cana-
kinumab is approved for the treatment of a group of autoinflam-
matory diseases now termed cryopyrin-associated periodic
syndromes (CAPS) that includes familial cold autoinflammatory
syndrome, Mucle-Wells syndrome, and Neonatal Onset Multi-
inflammatory Disease (see Essay by D.L. Kastner et al. in this
issue; Lachmann et al., 2009). Both canakinumab and Xoma940 Cell 140, 935–950, March 19, 2010 ª2010 Elsevier Inc.052 are in clinical trials for treating type 2 (and type 1) diabetes,
gout, Behcet’s disease, and other autoinflammatory diseases.
Rilonacept is a construct of the two extracellular domains of
the IL-1 receptor complex and binds to both IL-1a and IL-1b.
Rilonacept has been approved for the treatment of familial cold
autoinflammatory syndrome (Hoffman et al., 2008) and has
been used to treat gout. The extracellular domains of IL-1
receptor type II preferentially bind to IL-1b. However, for optimal
neutralization, the extracellular domain of IL-1 receptor acces-
sory protein is required and, in clinical testing, the type II receptor
was not effective. The extracellular domains of IL-1 receptor type
I, which preferentially bind to IL-1Ra and IL-1a, were not effective
in patients.
Is it possible to specifically inhibit IL-1 activity with orally active
agents? Currently, there are no orally active agents that prevent
the binding of IL-1 to its receptor. Nevertheless, orally active
agents that target the processing and secretion of IL-1b have
been developed. For IL-1b to be released from the cell as an
active cytokine, several steps are necessary (Figure 2). The puri-
nergic receptor P2X7 is activated by extracellular ATP and
appears to be a critical early step in the release of active IL-1b
(Netea et al., 2009; Perregaux et al., 2000). Once the purinergic
receptor P2X7 is activated, there is a rapid efflux of potassium
ions from the cell, subsequent oligomerization of the inflamma-
some, activation of caspase-1, cleavage of the IL-1b precursor,
and release of active IL-1b via secretory lysosomes. Orally
active, specific inhibitors of the P2X7 receptor reduce disease
in several models of inflammation and are being tested in
humans with rheumatoid arthritis. However, the P2X7 receptor
serves other cellular functions, and it is unclear to what extent
inhibition of this receptor contributes to the amelioration of
inflammation. Moreover, sites for caspase-1 activity are present
in four members of the IL-1 family: IL-1b, IL-18, IL-33, and
IL-1F7. In the case of IL-33, inhibition of caspase-1 decreases
the intracellular destruction of the IL-33 precursor. Orally active
caspase-1 inhibitors also reduce inflammation in several ani-
mal models of disease and are effective in humans with autoin-
flammatory diseases (Stack et al., 2005). However, similar to
inhibition of the P2X7 receptor, specific inhibition of caspase-1
will also impact processing of other IL-1 family members. More-
over, there are animal models of IL-1b-mediated disease that are
independent of caspase-1 processing of the IL-1b precursor.
Although the oligomerization of inflammasome components
initiates the conversion of pro-caspase-1 into the active enzyme
for processing the IL-1b precursor, there are ample examples
of caspase-1-independent activities of IL-1b. For example,
the inflammation induced by muscle injury results in a large
influx of neutrophils, tissue damage, and high IL-6 levels. This
response is absent in mice deficient in IL-1b but fully present in
mice deficient in caspase-1 (Fantuzzi et al., 1997). Intra-articular
injection of cell wall fragments derived from Streptococcus pyo-
genes into mice resulted in joint inflammation, cartilage destruc-
tion, and a robust infiltration of neutrophils. However, caspase-
1-deficient mice exhibited the same response (Joosten et al.,
2009). Similarly, injection of urate crystals intraperitoneally into
mice induced a brisk peritonitis in mice with or without cas-
pase-1 (Guma et al., 2009). These findings are important for the
pathogenesis of autoinflammatory diseases as non-caspase-1
processing of IL-1b in the extracellular compartment accounts
for IL-1b-mediated inflammation under conditions involving
elevated neutrophil activation. Neutrophil enzymes that can
process the IL-1b precursor include elastase, proteinase-3,
chymases, granzyme A, and cathepsin G (Fantuzzi et al., 1997;
Guma et al., 2009; Joosten et al., 2009). Proteinase-3 cleaves
the IL-1b precursor into an active molecule (Coeshott et al.,
1999; Joosten et al., 2009) (see Figure 1). Alpha-1 antitrypsin is
an endogenous inhibitor of elastase and proteinase-3 and
exhibits a broad range of anti-inflammatory properties (Lewis
et al., 2008).
Natural Inhibition of Cytokines
Some cytokines function as natural inhibitors of inflammation,
but are they useful therapeutically? Rabbits passively immunized
against their own endogenous IL-1 receptor antagonist (IL-1Ra)
experience severe colitis (Ferretti et al., 1994), andmice deficient
in IL-1Ra develop diseases such as destructive arthritis (Horai
et al., 2000), arteritis (Nicklin et al., 2000), and a psoriasis-like
skin disorder. Furthermore, mice deficient in endogenous IL-1Ra
develop aggressive tumors after exposure to carcinogens (Krelin
et al., 2007). These data support the concept that relative
amounts of IL-1 versus IL-1Ra affect the severity of some dis-
eases. A single-nucleotide polymorphism (SNP) is associated
with lower circulating levels of IL-1Ra (Larsen et al., 2009; Rafiq
et al., 2007) and a concomitant increase in type 2 diabetes
(Larsen et al., 2009). The same polymorphism is associated
with reduced survival in patients with colon carcinoma com-
pared to those with the wild-type allele (Graziano et al., 2009).
The notion of an imbalance between IL-1b and IL-1Ra has
gained considerable legitimacy with reports of infants bornwith a genetic abnormality that results in nonfunctional IL-1Ra
(Aksentijevevich et al., 2009; Reddy et al., 2009). Soon after birth,
the affected infants exhibit impressive local and systemic inflam-
mation. Unless treated with exogenous IL-1Ra, the infants die.
The infants suffer from multiple neutrophil-laden skin eruptions,
vasculitis, bone abnormalities with large numbers of osteoclasts,
osteolytic lesions, and sterile osteomyelitis. The inflammation
resembles an infection with sepsis-like multiorgan failure, but
all cultures were sterile for microbes. When treated with daily
IL-1Ra (anakinra), the inflammation abated and the bone lesions
were reversed. The infants are an extreme example of what
happens without functional IL-1Ra: the activity of endogenous
IL-1 is ‘‘unopposed’’ and IL-1-driven inflammation runs rampant.
From these studies, one can propose that the outcome of inflam-
mation is the balance of proinflammatory versus anti-inflamma-
tory cytokines (Dinarello, 2009b).
Systemic Inflammation
Sepsis is an example of severe systemic inflammation and falls
into the autoinflammatory class of diseases as macrophages
but not T cells play a dominant role. The first studies that blocked
cytokine activity in humanswere in patients with sepsis. The clin-
ical trials of IL-1 or TNF-a blockade were based on animal
models of systemic inflammation caused by lethal endotoxin or
live infection. The data from the animal studies were impressive:
blocking either IL-1 or TNF-a reduced mortality. Hence, it
seemed plausible that patients with sepsis could be treated by
reducing IL-1 or TNF-a activity. Despite sophisticated intensive
care, there are more than 500,000 deaths from sepsis annually
in the US. Consequently, millions of dollars have been invested
in the development of IL-1 and TNF-a blocking agents, and these
have been tested in placebo-controlled clinical trials in over
12,000 patients. Only marginal reductions in 28 day mortality
were achieved, insufficient to gain regulatory approval. A meta-
analysis of the clinical trial data concluded that a survival benefit
of blocking IL-1 or TNF-a was only observed in those patients
most likely to die (Eichacker et al., 2002).
Other anticytokine therapies such as blocking IL-4 or IL-5 in
the treatment of asthma were based on well-established animal
models of airway antigen challenge, yet the data in several
placebo-controlled trials did not show sufficient efficacy to war-
rant moving forward with these cytokine blockers. However, in
autoimmune diseases and autoinflammatory diseases, blocking
cytokines has proven consistently beneficial. The same IL-1
receptor antagonist and the same monoclonal antibodies to
TNF-a or soluble TNF receptors that failed in clinical trials for
sepsis have been approved for the treatment of rheumatoid
arthritis, Crohn’s disease, plaque psoriasis, and a spectrum of
autoinflammatory diseases.
Protease Inhibitors
Proteases play an important role in initiating as well as sustaining
inflammation. Many studies have focused on blocking matrix
metalloproteases in order to stabilize fragile plaques in arteries
or reduce the loss of cartilage in arthritic conditions. Posttransla-
tional cleavage of the N-terminal amino acids of certain chemo-
kines (CCL3, CCL5, and CCL23, for example) by proteases
increases their potency (some by over 100-fold). Inhibition of
proteinase-activated receptor 2 (PAR-2) reduces inflammationCell 140, 935–950, March 19, 2010 ª2010 Elsevier Inc. 941
in mouse models of rheumatoid arthritis. Inhibition of PAR-2 also
reduces the destruction of chondrocytes in cartilage by IL-1b.
Antibodies to complement factor 5 (C5) prevent its protease-
mediated conversion to C5a, the terminal component in com-
plement-mediated inflammation. Thus, inhibition of proteases
is a valid approach to controlling inflammation.
There are several serum protease inhibitors to combat
protease-mediated inflammation. The serum protein a-1 anti-
trypsin inhibits serine proteases including neutrophil elastase
and also proteinase-3. Activation of complement is also inhibited
by a-1 antitrypsin. Humans born with a genetic deficiency in a-1
antitrypsin develop pulmonary emphysema early in life, possi-
bly due to progressive destruction of lung alveoli due to insuffi-
cient inhibition of neutrophil-derived elastase by a-1 antitrypsin.
Although a-1 antitrypsin inhibits neutrophil-derived elastase
in vitro, it also blocks endotoxin-stimulated IL-1b and TNF-a
production by human blood monocytes and reduces transloca-
tion of the transcription factor NF-kB to the nucleus in response
to cytokine stimulation. Whole-blood cytokine production in
patients lacking a-1 antitrypsin is elevated but decreases fol-
lowing an infusion of exogenous a-1 antitrypsin (Pott et al.,
2009). Administration of exogenous a-1 antitrypsin to mice
protects against allograft rejection (Lewis et al., 2008) and blocks
IL-1b-induced death of insulin-producing pancreatic b cells
(Lewis et al., 2008); a-1 antitrypsin also prevents HIV-1 entry
into host cells in vitro (Shapiro et al., 2001; Munch et al., 2007).
Orally Active Anti-inflammatories
Several orally active, disease-modifying drugs used to treat
autoimmune diseases—methotrexate, cyclosporine, tacrolimus,
and rapamycin—also possess anti-inflammatory properties. The
most widely used of these is methotrexate, which is primarily an
antiproliferative agent due to its ability to inhibit dihydrofolate
reductase. However, methotrexate also decreases production
of TNF-a and chemokines in vivo. The antiangiogenic properties
of methotrexate may also contribute to its anti-inflammatory
profile. Cyclosporine, tacrolimus, and rapamycin are immuno-
suppressive agents, which are used broadly inmany clinical situ-
ations from preventing allograft rejection to treating psoriasis
and controlling vasculitis. Their primary mechanism of action is
as inhibitors of IL-2 and IFN-g production, which results in
lymphocytes producing less TNF-a. Reducing inflammation is
part of their effectiveness but is likely to be an indirect effect.
Colchicine, which binds to tubulin and blocks microtubule
formation, remains the standard of therapy for preventing
attacks of urate crystal arthritis (gout) and for treating the autoin-
flammatory disease familial Mediterranean fever (see Essay by
D.L. Kastner et al. in this issue). Colchicine is also used to treat
a variety of chronic inflammatory diseases including autoim-
mune biliary cirrhosis. The mechanism of action of colchicine is
to prevent the infiltration of neutrophils into inflamed tissues.
Colchicine also inhibits the mobility of monocytes and macro-
phages, and colchicine therapy in patients with familial Mediter-
ranean fever has dramatically reduced the development of life-
threatening amyloidosis. Both familial Mediterranean fever and
gouty arthritis are IL-1b-mediated diseases. For example, the
IL-1 receptor antagonist (anakinra) as well as monoclonal anti-
bodies to IL-1b (canakinumab) will reduce the pain and inflam-942 Cell 140, 935–950, March 19, 2010 ª2010 Elsevier Inc.mation of gouty arthritis. Similarly, in familial Mediterranean fever
and Behcet’s disease, blocking IL-1b results in a rapid and sus-
tained remission of inflammation.
In 1991, Gilla Kaplan reported that clinically achievable levels
of thalidomide inhibited endotoxin-induced TNF-a in human
blood monocytes (Sampaio et al., 1991). Thalidomide, orally
active and structurally related to glutamic acid, had caused
limb malformations in children born of mothers who used the
drug to combat nausea during pregnancy. Thalidomide was
approved to treat patients with leprosy and later, due to its anti-
angiogenic properties, was used widely to treat patients with
multiple myeloma. Its use in treating various autoimmune dis-
eases is based on its immunosuppressive effects and ability to
affect the production as well as the activities of several cytokines
including IL-1, IL-2, IL-6, IL-12, IL-23, TNF-a, and IFN-g. For
example, a beneficial effect of thalidomide in Crohn’s disease
patients is thought to be due to reduced TNF-a and IL-23
production. However, peripheral neuropathy and other adverse
effects are a major problem with thalidomide. New analogs of
this drug such as a-fluoro-4-aminothalidomide exhibit increased
potency in blocking cytokine production. Analogs increase
cAMP levels in macrophages by inhibiting phosphodiesterase-4,
which results in reduced TNF-a production. The anti-inflamma-
tory cytokine IL-10 is elevated in response to thalidomide
analogs (Thiele et al., 2002). The thalidomide analog lenalido-
mide has been approved in the US and Europe in combination
with dexamethasone as maintenance therapy for multiple mye-
loma (Falco et al., 2008). Although lenalidomide has reduced
neurotoxicity, a hypercoagulation state has been observed in
clinical trials. In controlled studies, lenalidomide failed to induce
remission or be effective for treating Crohn’s disease. Neverthe-
less, lenalidomide’s clinical benefit in multiple myeloma is due, in
part, to its anticytokine and antiangiogenic properties, and it
continues to be evaluated in the treatment of several chronic
autoimmune and autoinflammatory diseases.
Small-Molecule Inhibitors of Signal Transduction
It has been estimated that there are over 300 kinases that phos-
phorylate intracellular proteins, including autophosphorylation of
kinases themselves. A key kinase of interest is the p38 mitogen-
activated protein kinase (MAPK), which regulates several funda-
mental mediators of inflammation including cytokines, chemo-
kines, COX-2, and nitric oxide synthase. The discovery of p38
MAPK began with a screen for small molecules that inhibited
endotoxin-induced IL-1b production as part of a program to
developorallyactivedrugs for treating rheumatoidarthritis.Scien-
tists at SmithKlineBeecham found that one of the compounds
(SB20358) reduced IL-1b production and also reduced arthri-
tis in mice. In order to ascertain the mechanism of action of
SB20358, they radiolabeled the compound, added it to cell
lysates, and isolated an intracellular protein that was closely
related toHOG-1 (highosmoticglucose-1),which is found in yeast
and enables growth in high sugar concentrations (Kumar et al.,
1995). The induction of cytokines and chemokines by immune
cells treated with hyperosmotic concentrations of sodium chlo-
ride is dependent on p38 MAPK (Shapiro and Dinarello, 1995).
After the discovery of p38 MAPK in the drug screen, the next
step was to develop small-molecule inhibitors against the
several isoforms of p38 MAPK. In general, specific inhibitors of
p38 MAPK do not affect the downstream signaling component
c-Jun NH2-terminal kinase (JNK). Inhibitors of the p38 MAPK
a isoform reduce the production of IL-1b and TNF-a in endo-
toxin-stimulated human monocytes, whereas the b, g, and d iso-
form inhibitors are less effective. Most animal models for sepsis,
type 1 diabetes, rheumatoid arthritis, lupus, multiple sclerosis,
and inflammatory bowel disease exhibit marked improvement
when treated with pan-p38 MAPK inhibitors. The most studied
inhibitor of p38 MAPK is SB20358, which inhibits phosphoryla-
tion of its substrate ATF-2.
Orally active p38 MAPK inhibitors are well tolerated in phase I
clinical trials in healthy subjects, but hepatic toxicity is observed
with increasing doses. Clinical targets for orally active inhibitors
of p38 MAPK have focused on rheumatoid arthritis with limited
success. Although there is improvement in clinical scores in
rheumatoid arthritis patients treated with most p38 MAPK inhib-
itors, thewindow of efficacy and unwanted toxicity appears to be
narrow and some clinical trials have been halted. The develop-
ment of new p38 MAPK inhibitors for clinical testing continues
because the kinase plays such a central role in many inflamma-
tory processes (Marin et al., 2001).
Tyrosine kinases such as the Janus kinases (Jak) play a key
role in many proliferative diseases including leukemias and are
part of the angiogenic process in solid tumors. In rheumatoid
arthritis, the synovial membrane, usually a single-cell layer in
healthy subjects, proliferates and becomes vascularized. Like
a tumor, the proliferating synovium (pannus) invades and
destroys the surrounding joint. Jak3 is a tyrosine kinase that
drives the proliferation and differentiation of lymphocytes.
From in vitro studies, inhibition of the Jak signaling pathway
appears to be a strategy in treating rheumatoid arthritis and
possibly other chronic inflammatory conditions. Clinical trials of
the orally active Jak inhibitor CP-690550 in patients with rheu-
matoid arthritis, renal allografts, or psoriasis showed a reduction
in inflammation markers and improved quality of life for these
patients. Mechanisms of action include a reduction in dendritic
cell activation and proinflammatory cytokine production as well
as increased production of the anti-inflammatory cytokine
IL-10. A related Jak inhibitor reduced IL-17 and IFN-g production
by peripheral blood mononuclear cells. At higher doses, Jak
inhibitors are associated with increased serum creatinine levels,
indicating possible renal toxicity. An increase in infections,
nausea, abdominal pain, diarrhea, and dyspepsia have been
reported as the dose increases.
Spleen tyrosine kinase (Syk) participates in intracellular sig-
naling in B cells as well as in cells expressing Fc-g receptors.
Fc-g receptors are activated by IgG1 and are expressed by
monocytes, macrophages, neutrophils, and mast cells. A spe-
cific inhibitor of Syk reduced production of IL-1b, TNF-a, IL-6,
and IL-18. There are controversial data on whether Syk inhibits
IL-1b via the inflammasome (Gross et al., 2009; van de Veerdonk
et al., 2009a). In amousemodel of rheumatoid arthritis (collagen-
induced arthritis), Syk inhibition reduced bone erosion, pannus
formation, and synovitis. In a blinded, placebo-controlled clinical
study in patients with rheumatoid arthritis, who were unrespon-
sive to methotrexate, there was a rapid and significant improve-
ment in all parameters of disease severity. Matrix metalloprotei-nase 3 and serum IL-6 levels decreased within the first week.
However, side effects included gastrointestinal disturbances
and neutropenia (Weinblatt et al., 2008). Inhibition of Syk may
be a valid strategy for reducing inflammation in autoimmune
diseases.
Imatinib (Gleevec) is a tyrosine kinase inhibitor that is used
clinically to block the kinase activity of the BCR-ABL oncoprotein
in patients with chronic myeloid leukemia. Imatinib is also effec-
tive in ameliorating disease in a mouse model of rheumatoid
arthritis and in reducing TNF-a production by synovial fluid
mononuclear cells from patients with rheumatoid arthritis (Pania-
gua et al., 2006). This kinase inhibitor reduced TNF-a production
by human blood monocytes in response to lipopolysaccharide
but did not suppress production of the anti-inflammatory cyto-
kine IL-10. In murine models of acute hepatitis, imatinib pre-
vented TNF-a-dependent inflammatory damage to the liver
induced by injecting concanavalin A (Wolf et al., 2005). These
findings suggest that imatinib is able to act as an anti-inflamma-
tory because it reduces TNF-a production. It remains unclear
whether these observations will be of therapeutic value for treat-
ing TNF-a-mediated diseases.
Statins as Anti-inflammatory Agents
Mevalonate is the substrate for the synthesis of cholesterol as
well as several biologically active sterols. The generation of
mevalonate requires the reduction of the enzyme hydroxyme-
thylglutaryl-coenzyme A (HMG-CoA) by HMG-CoA reductase.
Synthetic small-molecule inhibitors of the reductase are called
‘‘statins.’’ Statins were developed to lower the endogenous
synthesis of cholesterol in patients at high risk for myocardial
infarction in whom elevated levels of low-density lipoproteins
(LDL) were difficult to control. Initial epidemiological studies
showed a highly significant reduction in cardiovascular events
with statin treatment, and the number of high-risk patients being
treated with statins increased rapidly. Several analogs of statins
that also inhibit HMG-CoA reductase entered clinical trials; it
became clear that all statins reduced LDL levels to the same
extent but that the decrease in cardiovascular events was
greater for some statins than for others. An analysis of the Fra-
mingham cohort (a long-term prospective study of the health
of residents of Framingham, MA, USA) for serum levels of
C-reactive protein (CRP) provided a value for predicting cardio-
vascular risk, although the association of elevated CRP with
inflammation in coronary artery disease was not new (Liuzzo
et al., 1994).
A large, placebo-controlled trial of nearly 18,000 patients eval-
uated the effect of rosuvastatin for cardiovascular events in
patients with normal LDL-cholesterol levels (less that 130
mg/dL). After 1.9 years, CRP decreased by 37% in the treatment
group and there were significantly fewer (range of 48%–55%)
cardiovascular events including stroke. Death from any cause
was 20% lower compared to the placebo group (Ridker et al.,
2008). The study known as the JUPITER trial raised the epide-
miological issue of the benefit of statins in apparently healthy
subjects. CRP levels above 2.0 mg/l, a biomarker for occult
inflammation including coronary artery inflammation, were
used as an entry criterion for the JUPITER trial (4% of the US
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conclusion of the study was that statins had anti-inflammatory
properties independent of their ability to lower cholesterol and
that reducing occult inflammation with statins could reduce
degenerative processes of aging.
The statin-mediated reduction in mevalonate also reduces the
synthesis of cholesterol via the isoprenoid pathway. The function
of several intracellular signaling molecules is also affected by
statins through a reduction in products of the isoprenoid path-
way that are important for the formation of signaling complexes.
There is no dearth of studies on the anti-inflammatory proper-
ties of statins in vitro and in animal models of autoimmune
and inflammatory diseases. In vitro, statins reduce cytokine
production and expression of endothelial adhesion molecules.
Statins decrease expression of major histocompatibility com-
plex (MHC) class II molecules but do not affect MHC class I.
They also downregulate the maturation of dendritic cells. Statins
bind to a unique allosteric site in b2 integrin known as lympho-
cyte function-associated antigen-1 (LFA-1), which participates
in many inflammatory processes. However, the anti-inflamma-
tory effect of binding to LFA-1 is independent of the inhibition
of HMG-CoA reductase. Fluvastatin induced apoptosis of
synovial cells from patients with rheumatoid arthritis through
a caspase-3 mechanism. Both atorvastatin and simvastatin
suppressed expression of the RANK ligand by fibroblast-like
synovial cells, and atorvastatin inhibited osteoclast forma-
tion in a coculture of peripheral blood mononuclear cells, sug-
gesting that statins may inhibit osteoclast formation and bone
destruction. However, studies on the anti-inflammatory effects
of statins in vitro have also yielded inconsistent data: some
studies report a reduction in cytokine production by human
blood monocytes, whereas others report an increase in cytokine
production (Kuijk et al., 2008). It seems that animal models reveal
consistent findings for the anti-inflammatory effects of statins.
It is important to note that although the anti-inflammatory
properties of statins are highly consistent in animal models,
statins do not lower cholesterol in mice. Many studies demon-
strate reduced disease severity in animals treated with clinically
achievable levels of statins and suffering from a variety of inflam-
matory conditions including colitis, uveitis, myocarditis experi-
mental allergic encephalitis, lethal sepsis, allograft rejection,
and asthma (Abeles and Pillinger, 2006).
Statins have been used to reduce inflammation, tame immune
cell activation, or arrest degenerative processes. Because of
their widespread use and long-term safety record, some physi-
cians prescribe statin therapy for nonapproved indications.
A number of case reports describe the dramatic effects of statins
added to standard therapies, but beneficial effects need to be
confirmed in controlled studies. For example, in three patients
with lupus glomerulonephritis who were not responding to
the standard of therapy (cyclophosphamide and prednisone),
adding high doses of simvastatin brought about a dramatic
reduction in disease activity. There are randomized, placebo-
controlled studies, but two issues cloud the results: the particular
statin used and the dose. Clearly the anti-inflammatory proper-
ties of statins vary, whereas the cholesterol-lowering properties
are similar. Six clinically used statins were examined in vitro for
their ability to affect NF-kB, phosphorylation of IkB, and activa-
tion of tissue factor, the first step in coagulation. There was944 Cell 140, 935–950, March 19, 2010 ª2010 Elsevier Inc.a distinct difference between the statins: cerivastatin, atorvasta-
tin, and simvastatin were more effective in reducing these
parameters than fluvastatin, lovastatin, or pravastatin (Hilgen-
dorff et al., 2003).
Nevertheless, there seems to be no dearth of case reports and
small uncontrolled trials that show the benefits of statins for
reducing inflammation. In the case of rheumatoid arthritis where
the anti-inflammatory effects of blocking cytokines have been
shown repeatedly, there have been more than ten trials of
statins resulting in a moderate reduction in joint inflammation
associated with a fall in CRP and red cell sedimentation rate
and decreased cytokine production by circulating monocytes.
As many patients with long-standing rheumatoid arthritis are
also at high risk for cardiovascular disease, adding statin therapy
to the standard of care (methotrexate) is highly cost effective.
Adding statins to the regimen of cyclosporine and sirolimus for
kidney transplant patients lowered the rate of organ rejection.
In patients with relapsing-remitting multiple sclerosis, statin
therapy for 6 months significantly lowered the number of brain
lesions detected by gadolinium, an established marker of
disease activity. Examination of peripheral blood cells revealed
no suppression in T cell responses but did reveal an increase
in production of IL-10, an anti-inflammatory cytokine (Paul
et al., 2008).
Histone Deacetylase Inhibitors
In order to compact chromatin, DNA is tightly wrapped around
nuclear histones, which are maintained in a state of deacetyla-
tion by histone deacetylases (HDACs). Histone acetylases, on
the other hand, hyperacetylate histones, unraveling DNA and
thus permitting transcription factors to bind to gene promoters
and initiate gene expression. In humans, there are 18 HDACs
divided into classes based on their dependence on zinc for enzy-
matic activity (Khan et al., 2008). In addition to their ability to
deacetylate the highly conserved N-terminal lysines of nuclear
histones, HDACs also target many non-histone-containing cyto-
plasmic proteins affecting ribosomal function, cytoskeletal poly-
merization, and signaling pathways.
Synthetic inhibitors of HDACs are orally active and usedwidely
in medicine. For example, valproic acid, the drug of choice for
treating epilepsy as well as obsessive disorders (Gerstner
et al., 2008), is an HDAC inhibitor (Ren et al., 2004). Valproic
acid has also been used in patients with HIV-1 to purge the
latently infected pool of memory T cells (Archin et al., 2008).
The HDAC inhibitor sodium butyrate is used to treat patients
with sickle cell anemia and b-thalassemia (Atweh and Schechter,
2001). The development of newer, small-molecule synthetic
inhibitors of HDACs began with the work of Paul Marks, a cancer
researcher (Marks et al., 2001). The goal was to inhibit HDACs
in order to increase the expression of several proapoptotic
genes that are often silenced in malignant cells. The first of
this class was the HDAC inhibitor suberoylanilide hydroxamic
acid (SAHA). At micromolar plasma concentrations, (O’Connor
et al., 2006) SAHA has been approved for treating patients with
cutaneous T cell leukemia (Santini et al., 2007) and has shown
benefit in the treatment of patients with acute myeloid leukemia
(Garcia-Manero et al., 2008). Many hematopoietic malignancies
appear to be responsive to HDAC inhibitors, possibly related
to the ability of these compounds to reduce the production of
cytokines, many of which are growth factors for leukemias and
myeloproliferative neoplasms (Guerini et al., 2008). Indeed,
HDAC inhibitors such as SAHA exhibit immunosuppressive
and anti-inflammatory properties by reducing cytokine produc-
tion (Leoni et al., 2002, 2005). Importantly, the anti-inflammatory
properties of HDAC inhibitors are observed in the low nanomolar
range compared to the micromolar range needed to treat can-
cer where the mechanism of action is to increase apoptosis by
upregulating expression of proapoptotic genes. The recent
expanding interest in HDAC inhibitors as orally active, safe,
anti-inflammatory agents has been fueled by the ability of these
inhibitors to reduce disease severity in several animal models of
inflammatory and autoimmune diseases (Table S2).
ITF2357 is a hydroxamic acid-containing, orally active inhibitor
targeting class I and II HDACs. In a phase II clinical trial in chil-
dren with active systemic onset juvenile idiopathic arthritis,
a daily oral dose of ITF2357 at 1.5 mg/kg for 12 weeks resulted
in no organ toxicity and a significant (p < 0.01) reduction in
parameters of systemic disease and the number of painful
joints in over 75% of patients (Vojinovic et al., 2008). At a dose of
1.5 mg/kg, the peak blood levels of ITF2357 were 125–200 nM,
which are the levels that inhibit cytokine production in vitro
and by cultured blood cells from subjects receiving the drug
in vivo (Oldoni et al., 2009). Given that targeting of IL-1-mediated
inflammation to protect pancreatic islets has been tested in
human trials (Donath et al., 2009; Larsen et al., 2007a), HDAC
inhibitors may be useful for preventing inflammation of pan-
creatic islet tissue. Indeed, the HDAC inhibitors SAHA and
ITF2357 reduced cytokine-mediated nitric oxide formation and
reversed the decline in insulin secretion by isolated islets (Larsen
et al., 2007b; Susick et al., 2007). In animalmodels of Alzheimer’s
disease, the most common neurodegenerative disease, HDAC
inhibitors (Larsen et al., 2007a) decreased b-amyloid production,
and effective neuroprotection was associated with increased
acetylation of histones (Kozikowski et al., 2009) (see Review by
C.K. Glass et al. in this issue). In a model of head trauma, the
anti-inflammatory properties of HDAC inhibitors helped to
prevent neurological impairment even when administered 24 hr
after the injury (Shein et al., 2009). Although the role of inflamma-
tion in Huntington’s disease is presently unclear, inhibition of
caspase-1 delays the onset of motor abnormalities in a mouse
model of this neurodegenerative disease (Charles et al., 1999)
and treatment with oral SAHA reduces disease severity (Hockly
et al., 2003) (Table S2).
Anticoagulants and Thrombolytics as Anti-inflammatory
Agents
Despite several randomized, placebo-controlled trials of anti-
inflammatory agents and anticytokine therapies, sepsis remains
a leading cause of death. The only approved agent for reducing
death in sepsis is activated protein C (aPC). Protein C is a natural
component of human serum and upon activation inhibits the
formation of thrombin and breaks down thrombi in blood vessels.
aPC drives fibrinolysis through inhibition of plasminogen-acti-
vator inhibitor-1.Asa therapeutic in septic patients, aPC is admin-
istered intravenously and restores circulation to hypoxic organs.
Perhaps more importantly, however, aPC exerts a number ofanti-inflammatory effects. For example, aPC blocks the pro-
duction of the proinflammatory cytokines IL-1b and TNF-a by
blocking the transcription factor NF-kB (Esmon, 2006) and p38
MAPK (Nold et al., 2007), decreasing apoptosis of endothelial
cells and inhibiting leukocyte adhesion and chemotaxis.
Similarly, other anticoagulants, which prevent the formation of
microthrombi on the endothelium thereby maintaining a blood
supply to organs,may also be useful as anti-inflammatory agents
(Figure 1). Low molecular weight heparins and antithrombin
exhibit anti-inflammatory effects in vivo, mostly by reducing
cytokine production and endothelial activation by thrombin.
However, in a controlled trial in septic patients, anti-thrombin did
not reach statistical significance for reducing all cause 28 day
mortality. Small-molecule antiplatelet agents used in patients
at risk for myocardial infarction also act as anti-inflammatory
agents. Although these small-molecule anticoagulants are used
primarily to prevent clot formation, it is likely that many patients
benefit from the anti-inflammatory properties of this drug class.
Inhibition of Activated Complement
Activation of complement results in the generation of the terminal
component, complement 5a (C5a). C5a binds to its receptor
C5aR and triggers the synthesis of cytokines, chemokines,
and adhesion molecules with the subsequent infiltration of
myeloid cells, mostly neutrophils, into the area of injury (Figure 1).
As such, C5a is a major cause of acute inflammation, and acti-
vated complement appears to contribute to nearly all inflamma-
tory processes. Not unexpectedly, there are natural inhibitors of
complement activation such as C1 inhibitor and soluble Crry,
which inhibit all complement activation pathways and target acti-
vation of C3 (Huang et al., 2008). Rheumatoid arthritis, immune
complex diseases, psoriasis, lupus nephritis, acute lung injury,
myocardial and cerebral infarction, and renal ischemia are
considered diseases in which the activity of C5a could be tar-
geted. Complement activation takes place in acute allograft
rejection. Eculizumab, a monoclonal antibody directed against
C5, hasbeen approved for the treatment of paroxysmal nocturnal
hemoglobinuria. A single chain of this antibody, pexelizumab, has
been extensively studied in clinical trials in models of ischemia.
Pexelizumab, which is directed against C5 and blocks the gener-
ation of C5a, has been used in acute ST-elevation myocardial
infarction (STEMI) and the coronary artery bypass graft (CABG)
procedure. Meta-analysis of over 15,000 patients from seven
clinical trials showed no overall benefit of the antibody when
added to the standardof care (Testa et al., 2008), but theantibody
did reduce the riskof deathby26% inpatientsundergoingCABG.
Another approach to preventing the inflammatory sequelae of
complement activation is direct inhibition of serine proteases.
Nafamostat mesilate is a small-molecule serine protease inhib-
itor that targets the formation of the C3/C5 convertases. Several
studies indicate that the interaction of macrophages or dendritic
cells with T cells results in activation of complement. In mice
with experimental autoimmune encephalomyelitis (a model of
multiple sclerosis), nafamostat attenuated central nervous sys-
tem inflammation, reduced demyelination, and decreased the
numbers of immune cells producing IFN-g and IL-17 (Li et al.,
2009). Orally active convertase inhibitors or small-molecule
antagonists of C5aR may become broadly useful for treatingCell 140, 935–950, March 19, 2010 ª2010 Elsevier Inc. 945
chronic inflammatory conditions. Although there was no benefit
in patients with active rheumatoid arthritis after 28 days of treat-
ment with an orally active antagonist of C5aR, targeting inflam-
mation by preventing the generation of C5a or blocking C5aR
with orally active small molecules holds considerable promise.
The Anti-inflammatory Effects of PPARs
Endogenous, intracellular mechanisms exist to tame inflamma-
tion by targeting gene expression of proinflammatory cytokines,
cell adhesion molecules, and genes such as COX-2 or inducible
nitric oxide synthase. The peroxisome proliferator-activator
receptors (PPARs) are members of the nuclear receptor super-
family. There are three separate gene products with highly con-
served DNA-binding domains: PPARa, PPARb/d, and PPARg.
Functionally, PPARs form heterodimers with retinoic acid recep-
tors. Although this interaction has downstream effects in the
regulation of glucose metabolism, PPAR agonists are anti-
inflammatory agents because they reduce expression of several
proinflammatory cytokines, most chemokines, and cell adhesion
molecules. There are several endogenous agonists of PPARs
such as prostacyclin. However, there are orally active synthetic
ligands for PPARg—rosiglitazone, pioglitazone, troglitazone,
and fenofibrate—that are used to treat insulin resistance in
patients with type 2 diabetes. These drugs belong to the chem-
ical class called thiazolidinediones (or glitazones).
In vitro, the PPARg agonist pioglitazone reduces synthesis and
gene expression of TLR2, TLR4, IL-1b, TNF-a, IL-6, and mono-
cyte chemoattractant protein-1 in human blood monocytes
(Dasu et al., 2009). In vivo, pioglitazone reduces lipopolysaccha-
ride-induced TLR2 and TLR4 expression on peritoneal macro-
phages (Dasu et al., 2009). In humans with type 2 diabetes, pio-
glitazone reduces serum CRP and TNF-a but increases VEGF
levels. Rosiglitazone improves insulin resistance by increasing
the production of the anti-inflammatory molecule adiponectin.
In a mouse model of lupus nephritis, oral treatment with pioglita-
zone decreases immune complex deposition, renal inflamma-
tion, and intrarenal synthesis of TNF-a, IL-1b, and VCAM-1
(Zhao et al., 2009).
Despite the anti-inflammatory portfolio of PPAR agonists,
some clinical studies indicate that treatment of type 2 dia-
betic patients with thiazolidinediones, particularly rosiglitazone,
increases cardiovascular events and death (Stafylas et al.,
2009). A meta-analysis of data on the cardiovascular safety of
glitazones concluded that clinical trials consistently indicate an
increased risk of heart failure. Some studies have shown that
pioglitazone may be beneficial for reducingmajor cardiovascular
outcomes. Whether using PPARg agonists as anti-inflammatory
agents will entail the same risks remains unknown. Nevertheless,
PPARg agonists as a class of orally active drugs with anti-inflam-
matory properties will certainly be developed.
Prostaglandin Agonists and Phosphodiesterase-4
Inhibitors
Although PGE2 is inflammatory and lowers pain thresholds, it is
also one of the most immunosuppressive natural products of
inflammation. One of the four receptors for PGE2 is EP4, and
selective EP4 agonists are anti-inflammatory. For example,
EP4 agonists reduced levels of proinflammatory cytokines, che-946 Cell 140, 935–950, March 19, 2010 ª2010 Elsevier Inc.mokines, and adhesion molecules. PGE2 is a potent inhibitor of
IFN-g and IL-2 production but increases IL-17 production.
In general, the immunosuppressive properties of PGE2 are due
to an increase in the intracellular levels of cyclic AMP (cAMP),
which suppresses production of TNF-a, IL-2, and IFN-g. In
fact, inhibitors of PGE2 synthesis result in lower levels of cAMP
and higher levels of TNF-a. Analogs of prostaglandin-I2 (iloprost,
cicaprost, treprostinil) inhibit the proinflammatory cytokines
IL-12, TNF-a, IL-1a, and IL-6 as well as the chemokines MIP-1a
and MCP-1 by boosting cAMP levels (Zhou et al., 2007).
Inhibitors of phosphodiesterase-4 (PDE-4) are anti-inflamma-
tory and immunosuppressive because they prevent the break-
down of cAMP. Rolipram, roflumilast, piclamilast, and pentoxi-
fylline are selective PDE-4 inhibitors that are in clinical use.
A general property of PDE-4 inhibitors is the suppression of cyto-
kine production aswell as degranulation by neutrophils and TNF-
a-induced neutrophil adherence to endothelial cells, which is
a fundamental step in inflammation. Some studies indicate that
rolipram and newer PDE-4 inhibitors are comparable or superior
to methylprednisolone in suppressing inflammation in models of
inflammatory bowel disease, atopic dermatitis, spinal cord
injury, septic shock, cerebral ischemia, and hyperoxia-induced
lung inflammation. PDE-4 inhibitors also decrease the binding
of NF-kB to DNA and the production of VEGF.Conclusions
In this Review, I have made a case that the future of anti-inflam-
matory agents lies in the development of orally active drugs that
reduce production or activities of proinflammatory cytokines.
In addition, particularly with respect to treating the inflammatory
component of degenerative diseases of aging, newer drugs
need to have minimal risks of organ toxicity while ensuring that
host immune defense against infection and cancer is not
impaired. Some drugs currently used to treat a variety of dis-
eases exhibit distinct anticytokine effects, for example, statins,
histone deacetylase inhibitors, and PPAR agonists. Based on
their long-term safety, increasing the anti-inflammatory and
anticytokine properties of these classes of drugs is warranted.
New agents are in a rapid stage of development, for example,
orally active chemokine receptor antagonists. Based on animal
studies, using small RNAs to downregulate gene expression
and targeting microRNAs that regulate gene expression holds
therapeutic promise. In addition, agents that increase the
expression and activities of endogenous anticytokines such as
the IL-1 receptor antagonist or IL-10 should be considered.
The understanding of the pivotal role of inflammation in seem-
ingly unrelated diseases has resulted in the use and develop-
ment of new anti-inflammatory agents such as the biologicals.
These have improved the quality as well as the duration of life
for millions of patients. In addition, it appears that combating
inflammation will slow the degenerative consequences of aging
such as atherosclerosis, joint disease, and neurodegeneration.SUPPLEMENTAL INFORMATION
Supplemental Information includes two tables and can be found with this
article online at doi:10.1016/j.cell.2010.02.043.
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